目的 探索心脈通膠囊聯(lián)合維拉帕米治療高血壓的臨床效果。方法 選取了2017年9月—2020年9月平頂山市第二人民醫(yī)院收治的128例高血壓患者為研究對(duì)象，按照隨機(jī)數(shù)字表法分為對(duì)照組和治療組，每組各64例。對(duì)照組口服鹽酸維拉帕米緩釋片，1片/次，2次/d；治療組在對(duì)照組基礎(chǔ)上口服心脈通膠囊，3粒/次，3次/d。兩組均連續(xù)服用4周。觀察兩組的臨床療效，比較兩組治療前后血壓和血清細(xì)胞因子的變化情況及不良反應(yīng)發(fā)生情況。結(jié)果 治療后，治療組總有效率89.06%，顯著高于對(duì)照組76.66%（P<0.05）。治療后，兩組舒張壓、收縮壓均較治療前顯著降低（P<0.05）；且治療后治療組舒張壓、收縮壓顯著低于對(duì)照組（P<0.05）。治療后，治療組血清C反應(yīng)蛋白（CRP）、基質(zhì)金屬蛋白酶9（MMP-9）、轉(zhuǎn)化生長(zhǎng)因子β1（TGF-β1）、單核細(xì)胞趨化因子（MCP）水平均顯著降低（P<0.05）；且治療后，治療組血清細(xì)胞因子水平顯著低于對(duì)照組（P<0.05）。治療過(guò)程中，治療組患者不良反應(yīng)發(fā)生率是3.13%，顯著低于對(duì)照組的18.75%（P<0.05）。結(jié)論 心脈通膠囊聯(lián)合維拉帕米治療高血壓患者具有較好的臨床療效，可降低血壓指標(biāo)和炎性因子水平，適合臨床推廣應(yīng)用。

Objective To explore the clinical effect of Xinmaitong Capsules combined with verapamil in treatment of hypertension. Methods A total of 128 patients with hypertension admitted to the Second People's Hospital of Pingdingshan from September 2017 to September 2020 were selected as the research objects, and they were divided into control and treatment group according to the random number table method, with 64 cases in each group. Patients in the control group were po administered with Verapamil Hydrochloride SR Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Xinmaitong Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the changes of blood pressure and serum cytokines were compared between the two groups before and after treatment. The incidence of adverse reactions in the two groups was observed. Results After treatment, the total effective rate in treatment group was 89.06%, which was significantly higher than 76.66% in control group (P < 0.05). After treatment, diastolic blood pressure and systolic blood pressure in both groups were significantly decreased compared with before treatment (P < 0.05). After treatment, diastolic blood pressure and systolic blood pressure in treatment group were significantly lower than those in control group (P < 0.05). After treatment, the levels of serum C-reactive protein (CRP), matrix metalloproteinase 9 (MMP-9), transforming growth factor β1 (TGF-β1) and monocyte chemokine (MCP) in treatment group were significantly decreased (P < 0.05). After treatment, serum cytokine level in treatment group was significantly lower than that in control group (P < 0.05). During the treatment, the incidence of adverse reactions in the treatment group was 3.13%, significantly lower than 18.75% in the control group (P < 0.05). Conclusions Xinmaitong Capsules combined with verapamil has good clinical effect in treatment of hypertension, and can reduce the level of blood pressure index and inflammatory factors, which is suitable for clinical application.

R972

河南省平頂山市科技計(jì)劃項(xiàng)目（2018-79）